Chapters Transcript Video ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD Back to Symposium Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer. This year. At as O we presented the final overall survival analysis from the tropics 02 study. This is a phase three trial in patients with metastatic hormone receptor positive breast cancer where they were randomized to get Azuma Gobain or treatment of physicians choice chemotherapy. This was a patient population that had progressed on prior endocrine therapy had had prior taxa and could have received 2 to 4 prior lines of chemotherapy in the metastatic setting. Here. Um At the final analysis, we have approximately 13 months of follow up and we saw that there was a consistent improvement in progression free survival as had been seen earlier from about four months to 5.5 months. And we also saw that there is a statistically significant improvement in overall survival going from 11.2 months to 14.5 months. Uh this is consistent with the hazard ratio of 0.79 and again, uh continues to show benefit even at the time of the final analysis. So I think overall these data do suggest that Sauza is associated with both the statistically significant improvement in PFS and OS compared to standard chemotherapy and endocrine refractory metastatic hormone receptor positive disease and does really represent a new standard option for our patients. Published June 21, 2023 Created by Related Presenters Sara Tolaney, MD, MPH Medical Oncology Chief, Division of Breast Oncology, Susan F. Smith Center for Women's Cancers View full profile
